Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment
Abstract Background Oncolytic viruses have pledged to combat cancer by causing immunogenic cell death of cancerous cells while priming cancer-specific immune responses. These outcomes have proven elusive in the clinic. Current-generation vectors rarely reach effective concentrations inside tumors when given intravenous...